Category: Markets
Published: 2026-07-02T09:33:07.000Z
KeyBanc has increased its price target for West Pharmaceutical Services (WST) to $390 from $350, while reiterating an "Overweight" rating on the stock. This adjustment reflects a positive outlook for the company from the analytical firm. The article also notes recent company activities, including the sale of SmartDose 3.5mL manufacturing rights and recent executive changes.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.